In the fall of 1999, a young chemical engineer named Todd Zion left his job at Eastman Kodak to enroll in the Ph.D. program at the Massachusetts Institute of Technology.
While looking for a subject to research, Zion noticed a grant proposal, never funded, that another graduate student had written on the subject of drug delivery. One possibility mentioned in the proposal was the development of a kind of insulin that would automatically respond to changes in blood-sugar levels, becoming active only when needed to maintain healthy levels around the clock. If it worked, the sugar-sensitive version could transform the lives of the six million people with diabetes in the United States who use insulin. No longer would they have to test their blood-sugar levels multiple times per day and try to calculate how much insulin to take. The self-regulating insulin would curtail high sugar levels, which raise the risk of long-term complications, and eradicate, or at least reduce, the most dangerous short-term complication: hypoglycemia, when sugar levels fall so low that they can cause confusion, unconsciousness, seizures and even death.
“I thought, Wow, that is a really neat area in which to do research,” Zion told me. Other researchers had been trying for 20 years to make insulin work only when needed. The first to publish a study were the scientists Michael Brownlee and Anthony Cerami, who in 1979 embedded a sugar-encrusted form of insulin in a mesh pouch with a sugar-loving protein called lectin. The idea was that when blood-sugar levels were elevated, the lectin would bind to the sugar in the blood and allow the insulin to leak out; when sugar levels were normal, the lectin would bind to the sugar-encrusted insulin, keeping it inside the pouch. But the system was impractical, because the pouch would need to be implanted under the skin and periodically refilled. And the lectin, derived from the jack-bean plant, was toxic.
In his first three years at M.I.T., Zion used nanoscale molecular engineering to create an insulin-lectin gel that could be injected without the need for an implanted pouch, while also rejiggering the lectin to make it less toxic. “It worked great visually,” he said. When the gel was placed in a sugar solution, “you could see the outer edge getting clear and dissolving . . . almost like an ice cube melting in water.”
The problem was that, no matter how hard he tried to manipulate the gel, the insulin either leaked out too easily, even when sugar levels were low, or not easily enough, when sugar levels were high.
Zion knew there was another approach: changing the insulin molecule itself, to make it sensitive to blood-sugar levels directly. But, he said, “almost everyone in the field of drug discovery believed that you should never, ever change the insulin molecule. . . . From a regulatory point of view, as soon as you manipulate the molecule, you’ve created a new drug. It doesn’t matter if you’ve attached a single atom to it.” Doing so, he knew, would require years of clinical trials in preparation for a new-drug application submission to the F.D.A. “That’s the only reason people were afraid.”
Zion’s trick was to attach a chemical arm — a short chain of sugars — directly onto the insulin molecule. (Attaching sugar to insulin? “Yes, it is a bit ironic,” he concedes.) The beauty of this approach is that it permits the insulin to latch directly onto the sugar-loving lectin in the gel — but only as needed. When blood-sugar levels are high, the lectin hooks up with any sugar floating freely from the blood, allowing the insulin molecule to do its normal job of connecting with insulin receptors on the surface of cells. (That is how insulin lowers blood-sugar levels, by merging with a cell’s insulin receptor and unlocking the cell membrane to allow sugar in.) When the sugar gets swallowed up by cells, lowering levels in the blood, the only remaining sweet for the lectin to attach to is the altered insulin’s sugar arm. Handcuffed to the lectin, the insulin can’t bind to insulin receptors. And so the insulin stops working to lower blood-sugar levels precisely when it’s no longer needed, because its sugar chain is held hostage by the lectin.
Zion called his new chemical creation smart insulin. In 2003, after testing it in rats, he won M.I.T.’s annual Entrepreneurship Competition. With the $30,000 prize money, he started a company called SmartCells and tried to see if he could make it work well enough to test it in humans.
The Latest on: Inventing drugs
[google_news title=”” keyword=”Inventing drugs” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Inventing drugs
- CONCHAIRTO ELEVATES THE FAN EXPERIENCE BY GETTING THEM TO TAKE A SEATon May 17, 2024 at 9:48 am
Most paramount, conCHAIRto lends itself to a safer environment for fans, organizers, and security, reducing the chances of illegal drugs, weapons, and other contraband finding their way into a festive ...
- FDA leaders talk adcomms, shortageson May 17, 2024 at 9:00 am
Senior FDA officials gave a series of mini-updates on policy and agency issues ahead of the anticipated election-season slowdown at the Food and Drug Law Institute’s annual conference in Washington ...
- Chemists develop new method for making gamma chiral centers on simple carboxylic acidson May 17, 2024 at 7:49 am
Scripps Research chemists have accomplished a long-elusive feat in synthetic chemistry: the invention of a broadly useful method for constructing "gamma chiral centers" on simple starting compounds ...
- AstraZeneca antibody reduced Covid-19 risk in immunocompromisedon May 17, 2024 at 6:05 am
AstraZeneca said that a new long-acting antibody reduced immunocompromised patients’ risks of contracting symptomatic Covid-19 infections in a large Phase 3 prevention trial. Still, it’s not clear ...
- Biotech CEO: Bayh-Dole 'fix' won't lower drug priceson May 17, 2024 at 2:11 am
A proposal to amend Bayh-Dole won’t, in fact, have the intended impact of reducing drug prices, writes John Glasspool, CEO of Anthos Therapeutics Inc. in Cambridge.
- Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peerson May 16, 2024 at 10:25 am
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, maker of the weight loss drug Wegovy, is tops, according to a new analysis. #STATBreakthrough ...
- MGB spinout gets $33M for injectable 'ice' to treat painon May 14, 2024 at 6:00 am
A Cambridge startup whose founding team includes an inventor of CoolSculpting technology is developing a temperature-driven injectable to treat acute and chronic pain.
- 'A lot of excitement' - Obesity drug cuts heart disease deaths by 20%on May 14, 2024 at 2:17 am
The obesity drug Ozempic cuts a person’s risk of dying from heart disease by 20%, new research has concluded. The five-year study by University College London tracked the health of 17,604 adults over ...
- 🔒 AI is inventing drugs – and it’s very exciting: Lisa Jarvison May 10, 2024 at 12:41 am
While a recent analysis of the nascent field suggests AI-invented drugs outperform human-invented ones in the earliest clinical stages, AI has yet to obviate the need for safety studies or replace ...
- Inventing Drugs Is One of the Most Exciting Uses of AIon May 9, 2024 at 8:30 am
It’s an important leap towards a world where technology enables a deeper understanding of human biology and, hopefully, improves our ability to discover new drugs. It was only two years ago that ...
via Bing News